同期放化疗后巩固化疗治疗局部晚期非小细胞肺癌的临床研究 |
| |
引用本文: | 柯柳杨,黄白云,程玉莲.同期放化疗后巩固化疗治疗局部晚期非小细胞肺癌的临床研究[J].现代保健,2012(16):9-11. |
| |
作者姓名: | 柯柳杨 黄白云 程玉莲 |
| |
作者单位: | 广东省农垦中心医院,广东湛江524200 |
| |
摘 要: | 目的 评价Ⅲ A、Ⅲ B 期非小细胞肺癌放疗联合TP 方案同期化疗后再给予TP 方案巩固化疗的临床价值.方法 选取2006年4月-2008 年4 月期间局部晚期非小细胞肺癌患者( Ⅲ A 期和Ⅲ B 期),采用TP 方案( 泰素+ 顺铂) 和三维适行放疗常规分割放疗方案同步化疗6 次后评价疗效.将治疗后达到CR、PR的患者随机分为巩固化疗组( 给予TP 方案化疗4 周期) 与对照组.按WHO 近期疗效及毒副标准评价治疗结果,用Ka-plan-Meier 法计算生存率.结果 共50 例患者入组,其中接受巩固化疗患者27 例,对照组23 例,巩固化疗组与对照组中位疾病无进展时间(TTP) 分别为16.2 个月、10.9 个月(P=0.037),总体中位生存时间(OS) 为21.6 月、15.7 个月(P=0.043).巩固化疗组毒副反应主要为骨髓抑制,但可耐受.患者1 年KPS 评分〉60 分者分别为70.4%(19/27)、73.9%(17/23)(P〉0.05).结论 TP 方案巩固化疗对非小细胞肺癌同期放化疗后达到CR 或PR 的患者有效且安全,能够改善无病生存时间.
|
关 键 词: | 非小细胞肺癌 同期放化疗 巩固化疗 TP 方案 |
Clinical Study on Concurrent Chemoradiotherapy Combined with Consolidation Chemotherapy in Treatment of Locally Advanced Non-small Cell Lung Cancer |
| |
Authors: | KE Liu-yang HUANG Bai-yun CHENG Yu-lian |
| |
Institution: | The Central Hospital of Guangdong Agricultural reclamation, Zhanjiang524200, China |
| |
Abstract: | Objective :To evaluate the effect of consolidation TP chemotherapy after concurrent chemoradiotherapy on stage m A and Ⅲ B NSCLC. Methods : Patients with stage Ⅲ NSCLC between April 2006 and April 2008 who received 3-dimensional eonformal radiotherapy (3D-CRT) combined with docetaxel and cisplatin regimen for 6 cycles were examined. Patients reached complete response(CR) or partial response(PR) were enrolled and derided into consolidation ehemotherapy group and eontrol group. Results :50 patients were enrolled, 27 patients of consolidation chemotherapy group had better time to progression (median, 16.2 vs. 10.9 months ;P= 0.037) but the same overall survival (median, 21.6 vs. 15.7 months ; P = 0.043) compared to the control group. The side effects were mostly bone marrow suppression but acceptable .The rate of patients with KPS score 〉60 were70.4%(19/27) vs 73.9% (17/23) (P〉0.05).Condusion : Consolidation therapy with TP regimen for stage Ⅲ A and Ⅲ B NSCLC patients after concurrent ehemoradiotherapy is feasible and safe, it produce significantly longer TTP. |
| |
Keywords: | NSCLC Concurrent chemotherapy and radiotherapy Consolidation chemotherapy TP regiment |
本文献已被 维普 等数据库收录! |
|